Hematology Strategic Roundup | July 13 – August 14, 2026
Hematology Strategic Roundup exploring Key Developments and Competitive Shifts……
Johnson & Johnson Firefly Bio Acquisition | Lucid Diligence Brief
Johnson & Johnson's $1 billion Firefly Bio acquisition highlights a…
Hematology Strategic Roundup | June 8–July 10, 2026
Key Strategic Developments and Competitive Shifts in Hematology Coverage: June…
Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Pfizer's HYMPAVZI FDA label expansion | Lucid Diligence Brief
Pfizer’s HYMPAVZI FDA label expansion covers children 6–11 and patients ≥12…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…